Evidence map›Paper›PMID 37041609›Full record

ArticleArthritis research & therapy2023

Levothyroxine use and longitudinal changes in thigh muscles in at-risk participants for knee osteoarthritis: preliminary analysis from Osteoarthritis Initiative cohort.

Bahram Mohajer, Kamyar Moradi, Ali Guermazi, Jennifer S R Mammen, David J Hunter, Frank W Roemer, Shadpour Demehri

Open access · goldAbstract read
In one paragraph

Article in Arthritis research & therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Review
  3. Observational
  4. Article
  5. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 4 countries.

Bahram MohajerMusculoskeletal Radiology, Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, 601 N Caroline St., JHOC 5165, Baltimore, MD, 21287, USA.
Kamyar MoradiTehran University of Medical Sciences, School of Medicine, Tehran, Iran.
Ali GuermaziDepartment of Radiology, Chobanian & Avedisian Boston University School of Medicine, Boston, MA, USA.
Jennifer S R MammenDivision of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
David J HunterRheumatology Department, Royal North Shore Hospital, St Leonards, 2065 NSW, Australia.
Frank W RoemerDepartment of Radiology, Chobanian & Avedisian Boston University School of Medicine, Boston, MA, USA.
Shadpour DemehriMusculoskeletal Radiology, Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, 601 N Caroline St., JHOC 5165, Baltimore, MD, 21287, USA. demehri2001@yahoo.com.
Johns Hopkins Medicine · USBoston University · USFriedrich-Alexander-Universität Erlangen-Nürnberg · DEJohns Hopkins University · USRoyal North Shore Hospital · AUTehran University of Medical Sciences · IR

Funding

DATA COORDINATING CENTER FOR THE OSTEOARTHRITIS INITIATIVEN01AR22258 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI NEVITT, MICHAEL · 2007 to 2011
$13.5M
Skeleton and Joint Degeneration with AgingP01AG066603 · NIA · JOHNS HOPKINS UNIVERSITY · PI CAO, XU · 2021 to 2025
$9.2M
CLINICAL CENTERS FOR THE OSTEOARTHRITIS INITIATIVEN01AR22259 · NIDCD · UNIVERSITY OF MARYLAND BALTIMORE · PI HOCHBERG, MARC C. · 2007 to 2011
$7.8M
Clinical Centers for the Osteoarthritis Initiative^Rhode IslandN01AR22262 · NIAMS · MEMORIAL HOSPITAL OF RHODE ISLAND · PI EATON, CHARLES B. · 2007 to 2010
$6.8M
CLINICAL CENTERS FOR THE OSTEOARTHRITIS INITIATIVEN01AR22261 · NIAMS · OHIO STATE UNIVERSITY RESEARCH FDN · PI JACKSON, REBECCA · 2007 to 2011
$6.2M
CLINICAL CENTERS FOR THE OSTEOARTHRITIS INITIATIVEN01AR22260 · NIDCD · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · 2007 to 2010
$6.1M
Effect of statin intake on Non-traumatic Generalized Knee OsteoarthritisR01AR079620 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI DEMEHRI, SHADPOUR · 2021 to 2025
$1.8M
Mechanisms of Hypothalamic-Pituitary-Thyroid Axis AgingR01AG064256 · NIA · JOHNS HOPKINS UNIVERSITY · PI MAMMEN, JENNIFER SOPHIE · 2020 to 2021
$684k
NEW PHARMACOLOGY ASPECTS RELATED TO CARBONIC ANHYDRASER01HL022258 · NHLBI · UNIVERSITY OF FLORIDA · PI MAREN, THOMAS H · 1985 to 1986
–
CLINICAL CENTERS FOR THE OSTEOARTHRITIS INITIATIVE-N01AR22260N01AR022260 · NIAMS · UNIVERSITY OF PITTSBURGH · PI KWOH, KENT · 2002 to 2006
–
CLINICAL CENTERS FOR THE OSTEOARTHRITIS INITIATIVE-N01AR22261N01AR022261 · NIAMS · OHIO STATE UNIVERSITY RESEARCH · PI JACKSON, REBECCA · 2002 to 2006
–
CLINICAL CENTER FOR THE OSTEOARTHRITIS-264022262-264022262N01AR022262 · NIAMS · THE MEMORIAL HOSPITAL · PI ASSAF, ANNLOUISE R. · 2002 to 2006
–
NHLBI NIH HHS N01AR22258NIAMS NIH HHS N01AR22259NIAMS NIH HHS N01AR22260NIAMS NIH HHS N01AR22261NIAMS NIH HHS N01AR22262NIAMS NIH HHS R01 AR079620NIA NIH HHS P01 AG066603NIA NIH HHS R01 AG064256
6 · The paper itself

Abstract

backgroundWe examined the association between levothyroxine use and longitudinal MRI biomarkers for thigh muscle mass and composition in at-risk participants for knee osteoarthritis (KOA) and their mediatory role in subsequent KOA incidence.

methodsUsing the Osteoarthritis Initiative (OAI) data, we included the thighs and corresponding knees of participants at risk but without established radiographic KOA (baseline Kellgren-Lawrence grade (KL) < 2). Levothyroxine users were defined as self-reported use at all annual follow-up visits until the 4th year and were matched with levothyroxine non-users for potential confounders (KOA risk factors, comorbidities, and relevant medications covariates) using 1:2/3 propensity score (PS) matching. Using a previously developed and validated deep learning method for thigh segmentation, we assessed the association between levothyroxine use and 4-year longitudinal changes in muscle mass, including cross-sectional area (CSA) and muscle composition biomarkers including intra-MAT (within-muscle fat), contractile percentage (non-fat muscle CSA/total muscle CSA), and specific force (force per CSA). We further assessed whether levothyroxine use is associated with an 8-year risk of standard KOA radiographic (KL ≥ 2) and symptomatic incidence (incidence of radiographic KOA and pain on most of the days in the past 12 months). Finally, using a mediation analysis, we assessed whether the association between levothyroxine use and KOA incidence is mediated via muscle changes.

resultsWe included 1043 matched thighs/knees (266:777 levothyroxine users:non-users; average ± SD age: 61 ± 9 years, female/male: 4). Levothyroxine use was associated with decreased quadriceps CSAs (mean difference, 95%CI: - 16.06 mm

conclusionsOur exploratory analyses suggest that levothyroxine use may be associated with loss of quadriceps muscle mass, which may also partially mediate the increased risk of subsequent KOA incidence. Study interpretation should consider underlying thyroid function as a potential confounder or effect modifier. Therefore, future studies are warranted to investigate the underlying thyroid function biomarkers for longitudinal changes in the thigh muscles.

Indexed as

Osteoarthritis, KneeQuadriceps MuscleThyroxineAgedBiomarkersFemaleHumansMaleMiddle AgedMuscle, SkeletalBiomarkersThyroxineKnee osteoarthritisLevothyroxineMRIMuscle degenerationThyroid

Identifiers

PMID37041609
PMCPMC10088133
OpenAlexW4364379630

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.